Clinical Trial Update: Dasatinib Holiday for Improved Tolerability [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update reports dasatinib holiday strategies to improve tolerability in chronic myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: University of Jena | Conditions: Myeloid Leukemia, Chronic | Phase 3 | Status: COMPLETED